U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06866080) titled 'A Study of LCAR-AIO in Subjects with Relapsed/Refractory Autoimmune Diseases' on March 04.
Brief Summary: This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory autoimmune diseases.
Study Start Date: Feb. 10
Study Type: INTERVENTIONAL
Condition:
Relapsed/refractory Autoimmune Diseases
Intervention:
BIOLOGICAL: LCAR-AIO T cells
Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
Recruitment Status: RECRUITING
Sponsor: Nanjing Legend Biotech Co.
Published by HT Digital Content Services with permissi...